급성 골수성 백혈병 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Acute Myeloid Leukaemia Therapeutics Market size is expected to reach USD 11.36 Billion in 2034 from USD 4.47 Billion (2025) growing at a CAGR of 10.92% during 2026-2034.

The global acute myeloid leukaemia (AML) therapeutics market is expanding due to the increasing incidence of blood cancers worldwide. AML is a rapidly progressing cancer that affects the bone marrow and blood cells, requiring immediate and specialized medical treatment. Advances in oncology research are leading to the development of new targeted therapies and treatment approaches for AML patients.

One of the key drivers of the AML therapeutics market is the growing investment in cancer research and drug development. Pharmaceutical companies are developing innovative therapies such as targeted drugs and immunotherapies to improve treatment outcomes. In addition, improved diagnostic technologies are enabling earlier detection of leukemia, which helps healthcare providers begin treatment sooner.

Looking forward, the AML therapeutics market is expected to witness continued growth as new treatment options become available. Personalized medicine and precision oncology approaches are helping doctors tailor treatments to individual patients. As research continues to advance, these innovations are expected to significantly improve survival rates and patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease

• Myeloblastic Leukemia
• Myelomonocytic Leukemia
• Promyelocytic Leukemia
• Monocytic Leukemia
• Other Diseases

By Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Other Treatments

By Route of Administration

• Parenteral
• Oral

By End Use

• Hospitals And Clinics
• Specialty Centers
• Homecare Setting
• Ambulatory Care Centers

COMPANIES PROFILED

• Astellas Pharma Inc, BristolMyers Squibb Company, Daiichi Sankyo Company Limited, Jazz Pharmaceuticals plc, Novartis AG, Otsuka Pharmaceuticals Co Ltd, Pfizer Inc, Rigel Pharmaceuticals Inc, Merck KGaA, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY DISEASE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease
• 4.2. Myeloblastic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Myelomonocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Promyelocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Monocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals And Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Homecare Setting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Ambulatory Care Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Disease
  • 8.2.2 By Treatment
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Disease
  • 8.3.2 By Treatment
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Disease
  • 8.4.2 By Treatment
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Disease
  • 8.5.2 By Treatment
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Disease
  • 8.6.2 By Treatment
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ACUTE MYELOID LEUKAEMIA THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Astellas Pharma Inc
  • 10.2.2 Bristol-Myers Squibb Company
  • 10.2.3 Daiichi Sankyo Company Limited
  • 10.2.4 Jazz Pharmaceuticals Plc
  • 10.2.5 Novartis AG
  • 10.2.6 Otsuka Pharmaceuticals Co. Ltd
  • 10.2.7 Pfizer Inc
  • 10.2.8 Rigel Pharmaceuticals Inc
  • 10.2.9 Merck KGaA
  • 10.2.10 Sanofi